expected to improve operating performance on a quarter by quarter
- Product sales of $5.8 million in the fourth quarter increased 4%
compared to the fourth quarter of 2006 with the inclusion of freight
charges in product sales revenues, which began on April 1, 2007.
Excluding freight charges, product sales in the fourth quarter of
2007 decreased slightly compared to the same period in 2006. The
Company temporarily suspended production early in the third quarter
of 2007 of a private label radioactive product for one customer.
This product historically contributed $350,000 to quarterly
revenues. The customer will either permanently withdraw this product
from the market or make formulation changes and their decision is
expected in the first half of 2008. Revenues for all of 2007
increased 8% from $21.5 million in 2006 to $23.2 million in 2007,
driven by the inclusion of freight charges in revenues.
The radiopharmaceutical segment was also impacted by an industry
shortage of medical isotopes in December 2007 as a result of an
extended shutdown at a global supplier of these radioactive
isotopes.The Company has an alternative approved source of supply
for its raw materials and was able to fill all customer orders but
the shutdown affected the ability of radiopharmacies to carry out
procedures resulting in lower than anticipated demand.
- Product gross margins for the quarter ended December 31, 2007 were
49% compared to 61% for the fourth quarter of 2006, due to the
dilutive impact of including freight charges billed back to
customers in revenues and cost of goods sold beginning on April 1,
2007, coupled with foreign ex
|SOURCE DRAXIS Health Inc.|
Copyright©2008 PR Newswire.
All rights reserved